© Reuters. FILE PHOTO: Vial with the AstraZeneca’s coronavirus disease (COVID-19) vaccine is pictured in Berlin
BERLIN (Reuters) – Germany’s vaccine advisory committee sees no disadvantages or risks from giving younger recipients of AstraZeneca (NASDAQ:)’s COVID-19 vaccine a second dose of an alternative shot, two of its members said on Wednesday.
“Nobody expects from an immunological perspective that there will be a disadvantage to getting a second dose of another vaccine,” Marianne Roebl-Mathieu, a member of the standing committee on vaccinations, told an online briefing.
Studies involving mixing vaccine doses are underway.
The German committee recommended last week that people aged under 60 who had received one shot of the AstraZeneca vaccine should get a second dose of another vaccine following reports of rare blood clotting events.
Should a second dose prove ineffective, a third dose could be effective, added Roeble Mathieu. Her colleague on the panel, Christian Bogdan, said he had seen no evidence linking other vaccines to the rare blood clotting disorders.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.